Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
17,797
archived clinical trials in
Peripheral Vascular Disease

Effect of Resistance Training on Tobacco-Related Cardiovascular Disease Risk
Effect of Resistance Training on Tobacco-Related Cardiovascular Disease Risk
Status: Enrolling
Updated:  10/11/2012
University of California at Los Angeles
mi
from
Los Angeles, CA
Effect of Resistance Training on Tobacco-Related Cardiovascular Disease Risk
Effect of Resistance Training on Tobacco-Related Cardiovascular Disease Risk
Status: Enrolling
Updated: 10/11/2012
University of California at Los Angeles
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Veterans Service Organizations and MHV
Working With Veterans Organizations to Encourage Use of My HealtheVet
Status: Enrolling
Updated:  10/12/2012
Clement J. Zablocki VAMC
mi
from
Milwaukee, WI
Veterans Service Organizations and MHV
Working With Veterans Organizations to Encourage Use of My HealtheVet
Status: Enrolling
Updated: 10/12/2012
Clement J. Zablocki VAMC
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Non-Invasive EndoPAT Increases Diagnostic Yield of CAD by Coronary Angiography
Non-Invasive Peripheral Arterial Tonometry (EndoPAT) Increases Diagnostic Yield of Coronary Artery Disease by Coronary Angiography
Status: Enrolling
Updated:  10/23/2012
Mayo Clinic Rochester
mi
from
Rochester, MN
Non-Invasive EndoPAT Increases Diagnostic Yield of CAD by Coronary Angiography
Non-Invasive Peripheral Arterial Tonometry (EndoPAT) Increases Diagnostic Yield of Coronary Artery Disease by Coronary Angiography
Status: Enrolling
Updated: 10/23/2012
Mayo Clinic Rochester
mi
from
Rochester, MN
Click here to add this to my saved trials
Promotora-based Latino Family CVD Risk Reduction
Promotora-based Latino Family CVD Risk Reduction: Remaking the Home Environment
Status: Enrolling
Updated:  10/24/2012
Roybal Comprehensive Health Center
mi
from
Los Angeles, CA
Promotora-based Latino Family CVD Risk Reduction
Promotora-based Latino Family CVD Risk Reduction: Remaking the Home Environment
Status: Enrolling
Updated: 10/24/2012
Roybal Comprehensive Health Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Reduction of Mortality Prior to and During the First 90 Days of Dialysis Through a Renal Rehabilitation Program
Status: Enrolling
Updated:  10/25/2012
Maine Nephrology Associates
mi
from
Portland, ME
Reduction of Mortality Prior to and During the First 90 Days of Dialysis Through a Renal Rehabilitation Program
Status: Enrolling
Updated: 10/25/2012
Maine Nephrology Associates
mi
from
Portland, ME
Click here to add this to my saved trials
Evaluation of Coronary Luminal Diameter Enlargement With Emerge™ 1.20 mm PTCA Dilatation Catheter
EMERGE: Evaluation of Coronary Luminal Diameter Enlargement With Emerge™ 1.20 mm PTCA Dilatation Catheter
Status: Enrolling
Updated:  10/30/2012
Piedmont Heart Institute
mi
from
Atlanta, GA
Evaluation of Coronary Luminal Diameter Enlargement With Emerge™ 1.20 mm PTCA Dilatation Catheter
EMERGE: Evaluation of Coronary Luminal Diameter Enlargement With Emerge™ 1.20 mm PTCA Dilatation Catheter
Status: Enrolling
Updated: 10/30/2012
Piedmont Heart Institute
mi
from
Atlanta, GA
Click here to add this to my saved trials
Stem Cell Implantation in Patients Undergoing CABG
Stem Cell Implantation in Patients Undergoing CABG
Status: Enrolling
Updated:  11/2/2012
Univ of Pennsylvania
mi
from
Philadelphia, PA
Stem Cell Implantation in Patients Undergoing CABG
Stem Cell Implantation in Patients Undergoing CABG
Status: Enrolling
Updated: 11/2/2012
Univ of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) and Mobilization of Progenitor Cells in Peripheral Arterial Disease
Granulocyte-Macrophage Stimulating Factor (GM-CSF) and Mobilization of Progenitor Cells in Peripheral Arterial Disease: A Phase II Randomized Study
Status: Enrolling
Updated:  11/6/2012
Emory University
mi
from
Atlanta, GA
Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) and Mobilization of Progenitor Cells in Peripheral Arterial Disease
Granulocyte-Macrophage Stimulating Factor (GM-CSF) and Mobilization of Progenitor Cells in Peripheral Arterial Disease: A Phase II Randomized Study
Status: Enrolling
Updated: 11/6/2012
Emory University
mi
from
Atlanta, GA
Click here to add this to my saved trials
Handheld Echocardiography in Clinical Practice
Handheld Echocardiography in Clinical Practice
Status: Enrolling
Updated:  11/7/2012
Mayo Clinic Rochester
mi
from
Rochester, MN
Handheld Echocardiography in Clinical Practice
Handheld Echocardiography in Clinical Practice
Status: Enrolling
Updated: 11/7/2012
Mayo Clinic Rochester
mi
from
Rochester, MN
Click here to add this to my saved trials
Transseptal Needle Versus Radiofrequency Energy for Left Atrial Access
Transseptal Needle Versus Radiofrequency Energy for Left Atrial Access (TRAVERSE-LA): A Randomized Controlled Trial
Status: Enrolling
Updated:  11/8/2012
University of California, San Francisco
mi
from
San Francisco, CA
Transseptal Needle Versus Radiofrequency Energy for Left Atrial Access
Transseptal Needle Versus Radiofrequency Energy for Left Atrial Access (TRAVERSE-LA): A Randomized Controlled Trial
Status: Enrolling
Updated: 11/8/2012
University of California, San Francisco
mi
from
San Francisco, CA
Click here to add this to my saved trials
Albumin in Acute Ischemic Stroke Trial
A Phase III Randomized Multicenter Clinical Trial Of High-Dose Human Albumin Therapy For Neuroprotection In Acute Ischemic Stroke
Status: Enrolling
Updated:  11/14/2012
Mayo Clinic Hospital
mi
from
Phoenix, AZ
Albumin in Acute Ischemic Stroke Trial
A Phase III Randomized Multicenter Clinical Trial Of High-Dose Human Albumin Therapy For Neuroprotection In Acute Ischemic Stroke
Status: Enrolling
Updated: 11/14/2012
Mayo Clinic Hospital
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Albumin in Acute Ischemic Stroke Trial
A Phase III Randomized Multicenter Clinical Trial Of High-Dose Human Albumin Therapy For Neuroprotection In Acute Ischemic Stroke
Status: Enrolling
Updated:  11/14/2012
University of Arizona
mi
from
Tucson, AZ
Albumin in Acute Ischemic Stroke Trial
A Phase III Randomized Multicenter Clinical Trial Of High-Dose Human Albumin Therapy For Neuroprotection In Acute Ischemic Stroke
Status: Enrolling
Updated: 11/14/2012
University of Arizona
mi
from
Tucson, AZ
Click here to add this to my saved trials
Albumin in Acute Ischemic Stroke Trial
A Phase III Randomized Multicenter Clinical Trial Of High-Dose Human Albumin Therapy For Neuroprotection In Acute Ischemic Stroke
Status: Enrolling
Updated:  11/14/2012
University of California San Francisco and affiliated hospitals
mi
from
San Francisco, CA
Albumin in Acute Ischemic Stroke Trial
A Phase III Randomized Multicenter Clinical Trial Of High-Dose Human Albumin Therapy For Neuroprotection In Acute Ischemic Stroke
Status: Enrolling
Updated: 11/14/2012
University of California San Francisco and affiliated hospitals
mi
from
San Francisco, CA
Click here to add this to my saved trials
Albumin in Acute Ischemic Stroke Trial
A Phase III Randomized Multicenter Clinical Trial Of High-Dose Human Albumin Therapy For Neuroprotection In Acute Ischemic Stroke
Status: Enrolling
Updated:  11/14/2012
Stanford Medical Center
mi
from
Stanford, CA
Albumin in Acute Ischemic Stroke Trial
A Phase III Randomized Multicenter Clinical Trial Of High-Dose Human Albumin Therapy For Neuroprotection In Acute Ischemic Stroke
Status: Enrolling
Updated: 11/14/2012
Stanford Medical Center
mi
from
Stanford, CA
Click here to add this to my saved trials
Albumin in Acute Ischemic Stroke Trial
A Phase III Randomized Multicenter Clinical Trial Of High-Dose Human Albumin Therapy For Neuroprotection In Acute Ischemic Stroke
Status: Enrolling
Updated:  11/14/2012
University of Miami
mi
from
Miami, FL
Albumin in Acute Ischemic Stroke Trial
A Phase III Randomized Multicenter Clinical Trial Of High-Dose Human Albumin Therapy For Neuroprotection In Acute Ischemic Stroke
Status: Enrolling
Updated: 11/14/2012
University of Miami
mi
from
Miami, FL
Click here to add this to my saved trials
Albumin in Acute Ischemic Stroke Trial
A Phase III Randomized Multicenter Clinical Trial Of High-Dose Human Albumin Therapy For Neuroprotection In Acute Ischemic Stroke
Status: Enrolling
Updated:  11/14/2012
The Villages Research Group
mi
from
Ocala, FL
Albumin in Acute Ischemic Stroke Trial
A Phase III Randomized Multicenter Clinical Trial Of High-Dose Human Albumin Therapy For Neuroprotection In Acute Ischemic Stroke
Status: Enrolling
Updated: 11/14/2012
The Villages Research Group
mi
from
Ocala, FL
Click here to add this to my saved trials
Albumin in Acute Ischemic Stroke Trial
A Phase III Randomized Multicenter Clinical Trial Of High-Dose Human Albumin Therapy For Neuroprotection In Acute Ischemic Stroke
Status: Enrolling
Updated:  11/14/2012
Emory University and Grady Memorial Hospital
mi
from
Atlanta, GA
Albumin in Acute Ischemic Stroke Trial
A Phase III Randomized Multicenter Clinical Trial Of High-Dose Human Albumin Therapy For Neuroprotection In Acute Ischemic Stroke
Status: Enrolling
Updated: 11/14/2012
Emory University and Grady Memorial Hospital
mi
from
Atlanta, GA
Click here to add this to my saved trials
Albumin in Acute Ischemic Stroke Trial
A Phase III Randomized Multicenter Clinical Trial Of High-Dose Human Albumin Therapy For Neuroprotection In Acute Ischemic Stroke
Status: Enrolling
Updated:  11/14/2012
University of Kentucky
mi
from
Lexington, KY
Albumin in Acute Ischemic Stroke Trial
A Phase III Randomized Multicenter Clinical Trial Of High-Dose Human Albumin Therapy For Neuroprotection In Acute Ischemic Stroke
Status: Enrolling
Updated: 11/14/2012
University of Kentucky
mi
from
Lexington, KY
Click here to add this to my saved trials
Albumin in Acute Ischemic Stroke Trial
A Phase III Randomized Multicenter Clinical Trial Of High-Dose Human Albumin Therapy For Neuroprotection In Acute Ischemic Stroke
Status: Enrolling
Updated:  11/14/2012
Henry Ford Hospital and affiliated hospitals
mi
from
Detroit, MI
Albumin in Acute Ischemic Stroke Trial
A Phase III Randomized Multicenter Clinical Trial Of High-Dose Human Albumin Therapy For Neuroprotection In Acute Ischemic Stroke
Status: Enrolling
Updated: 11/14/2012
Henry Ford Hospital and affiliated hospitals
mi
from
Detroit, MI
Click here to add this to my saved trials
Albumin in Acute Ischemic Stroke Trial
A Phase III Randomized Multicenter Clinical Trial Of High-Dose Human Albumin Therapy For Neuroprotection In Acute Ischemic Stroke
Status: Enrolling
Updated:  11/14/2012
Wayne State and affiliated hospitals
mi
from
Detroit, MI
Albumin in Acute Ischemic Stroke Trial
A Phase III Randomized Multicenter Clinical Trial Of High-Dose Human Albumin Therapy For Neuroprotection In Acute Ischemic Stroke
Status: Enrolling
Updated: 11/14/2012
Wayne State and affiliated hospitals
mi
from
Detroit, MI
Click here to add this to my saved trials
Albumin in Acute Ischemic Stroke Trial
A Phase III Randomized Multicenter Clinical Trial Of High-Dose Human Albumin Therapy For Neuroprotection In Acute Ischemic Stroke
Status: Enrolling
Updated:  11/14/2012
University of Minnesota and affiliated hospitals
mi
from
Minneapolis, MN
Albumin in Acute Ischemic Stroke Trial
A Phase III Randomized Multicenter Clinical Trial Of High-Dose Human Albumin Therapy For Neuroprotection In Acute Ischemic Stroke
Status: Enrolling
Updated: 11/14/2012
University of Minnesota and affiliated hospitals
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Albumin in Acute Ischemic Stroke Trial
A Phase III Randomized Multicenter Clinical Trial Of High-Dose Human Albumin Therapy For Neuroprotection In Acute Ischemic Stroke
Status: Enrolling
Updated:  11/14/2012
Millard Fillmore Gates Hospital
mi
from
Buffalo, NY
Albumin in Acute Ischemic Stroke Trial
A Phase III Randomized Multicenter Clinical Trial Of High-Dose Human Albumin Therapy For Neuroprotection In Acute Ischemic Stroke
Status: Enrolling
Updated: 11/14/2012
Millard Fillmore Gates Hospital
mi
from
Buffalo, NY
Click here to add this to my saved trials
Albumin in Acute Ischemic Stroke Trial
A Phase III Randomized Multicenter Clinical Trial Of High-Dose Human Albumin Therapy For Neuroprotection In Acute Ischemic Stroke
Status: Enrolling
Updated:  11/14/2012
University Hospital and affiliated hospitals
mi
from
Cincinnati, OH
Albumin in Acute Ischemic Stroke Trial
A Phase III Randomized Multicenter Clinical Trial Of High-Dose Human Albumin Therapy For Neuroprotection In Acute Ischemic Stroke
Status: Enrolling
Updated: 11/14/2012
University Hospital and affiliated hospitals
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Albumin in Acute Ischemic Stroke Trial
A Phase III Randomized Multicenter Clinical Trial Of High-Dose Human Albumin Therapy For Neuroprotection In Acute Ischemic Stroke
Status: Enrolling
Updated:  11/14/2012
Oregon Health Science University and affiliated sites
mi
from
Portland, OR
Albumin in Acute Ischemic Stroke Trial
A Phase III Randomized Multicenter Clinical Trial Of High-Dose Human Albumin Therapy For Neuroprotection In Acute Ischemic Stroke
Status: Enrolling
Updated: 11/14/2012
Oregon Health Science University and affiliated sites
mi
from
Portland, OR
Click here to add this to my saved trials
Albumin in Acute Ischemic Stroke Trial
A Phase III Randomized Multicenter Clinical Trial Of High-Dose Human Albumin Therapy For Neuroprotection In Acute Ischemic Stroke
Status: Enrolling
Updated:  11/14/2012
University of Pennsylvania - Abington Hospital
mi
from
Abington, PA
Albumin in Acute Ischemic Stroke Trial
A Phase III Randomized Multicenter Clinical Trial Of High-Dose Human Albumin Therapy For Neuroprotection In Acute Ischemic Stroke
Status: Enrolling
Updated: 11/14/2012
University of Pennsylvania - Abington Hospital
mi
from
Abington, PA
Click here to add this to my saved trials
Albumin in Acute Ischemic Stroke Trial
A Phase III Randomized Multicenter Clinical Trial Of High-Dose Human Albumin Therapy For Neuroprotection In Acute Ischemic Stroke
Status: Enrolling
Updated:  11/14/2012
University of Texas - Memorial Hermann
mi
from
Houston, TX
Albumin in Acute Ischemic Stroke Trial
A Phase III Randomized Multicenter Clinical Trial Of High-Dose Human Albumin Therapy For Neuroprotection In Acute Ischemic Stroke
Status: Enrolling
Updated: 11/14/2012
University of Texas - Memorial Hermann
mi
from
Houston, TX
Click here to add this to my saved trials
Albumin in Acute Ischemic Stroke Trial
A Phase III Randomized Multicenter Clinical Trial Of High-Dose Human Albumin Therapy For Neuroprotection In Acute Ischemic Stroke
Status: Enrolling
Updated:  11/14/2012
Froedtert Memorial Hospital
mi
from
Milwaukee, WI
Albumin in Acute Ischemic Stroke Trial
A Phase III Randomized Multicenter Clinical Trial Of High-Dose Human Albumin Therapy For Neuroprotection In Acute Ischemic Stroke
Status: Enrolling
Updated: 11/14/2012
Froedtert Memorial Hospital
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Albumin in Acute Ischemic Stroke Trial
A Phase III Randomized Multicenter Clinical Trial Of High-Dose Human Albumin Therapy For Neuroprotection In Acute Ischemic Stroke
Status: Enrolling
Updated:  11/14/2012
John Muir Medical Centers
mi
from
Walnut Creek and Concord, CA
Albumin in Acute Ischemic Stroke Trial
A Phase III Randomized Multicenter Clinical Trial Of High-Dose Human Albumin Therapy For Neuroprotection In Acute Ischemic Stroke
Status: Enrolling
Updated: 11/14/2012
John Muir Medical Centers
mi
from
Walnut Creek and Concord, CA
Click here to add this to my saved trials
Albumin in Acute Ischemic Stroke Trial
A Phase III Randomized Multicenter Clinical Trial Of High-Dose Human Albumin Therapy For Neuroprotection In Acute Ischemic Stroke
Status: Enrolling
Updated:  11/14/2012
New York Presbyterian and affiliated hospitals
mi
from
New York City, NY
Albumin in Acute Ischemic Stroke Trial
A Phase III Randomized Multicenter Clinical Trial Of High-Dose Human Albumin Therapy For Neuroprotection In Acute Ischemic Stroke
Status: Enrolling
Updated: 11/14/2012
New York Presbyterian and affiliated hospitals
mi
from
New York City, NY
Click here to add this to my saved trials
Albumin in Acute Ischemic Stroke Trial
A Phase III Randomized Multicenter Clinical Trial Of High-Dose Human Albumin Therapy For Neuroprotection In Acute Ischemic Stroke
Status: Enrolling
Updated:  11/14/2012
University of Calgary
mi
from
Calgary,
Albumin in Acute Ischemic Stroke Trial
A Phase III Randomized Multicenter Clinical Trial Of High-Dose Human Albumin Therapy For Neuroprotection In Acute Ischemic Stroke
Status: Enrolling
Updated: 11/14/2012
University of Calgary
mi
from
Calgary,
Click here to add this to my saved trials
A Clinical Trial for People HIV+ Age > 50 at Risk for Heart Disease
Telmisartan and Flow-Mediated Dilatation in Older HIV-Infected Patients at Risk for Cardiovascular Disease
Status: Enrolling
Updated:  11/14/2012
UCLA CARE Ctr
mi
from
Los Angeles, CA
A Clinical Trial for People HIV+ Age > 50 at Risk for Heart Disease
Telmisartan and Flow-Mediated Dilatation in Older HIV-Infected Patients at Risk for Cardiovascular Disease
Status: Enrolling
Updated: 11/14/2012
UCLA CARE Ctr
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Sildenafil in Single Ventricle Patients
Safety, Pharmacokinetics and Hemodynamic Efficacy of Sildenafil in Single Ventricle Patients
Status: Enrolling
Updated:  11/30/2012
Duke Univ Med Ctr
mi
from
Durham, NC
Sildenafil in Single Ventricle Patients
Safety, Pharmacokinetics and Hemodynamic Efficacy of Sildenafil in Single Ventricle Patients
Status: Enrolling
Updated: 11/30/2012
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
Prediction of Feeding Problems in Prostaglandin-dependent Prematurely Born Infants With Congenital Heart Disease
Prediction of Feeding Problems in Prostaglandin-dependent Prematurely Born Infants With Congenital Heart Disease
Status: Enrolling
Updated:  12/5/2012
Primary Children's Medical Center
mi
from
Salt Lake City, UT
Prediction of Feeding Problems in Prostaglandin-dependent Prematurely Born Infants With Congenital Heart Disease
Prediction of Feeding Problems in Prostaglandin-dependent Prematurely Born Infants With Congenital Heart Disease
Status: Enrolling
Updated: 12/5/2012
Primary Children's Medical Center
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Validation of Peripheral Pressure Volume Loops and Ultrasound-derived "Cardiac Power" by Comparison With Invasive Left Ventricular Pressure Volume Loops
Status: Enrolling
Updated:  12/12/2012
University of Virginia
mi
from
Charlottesville, VA
Validation of Peripheral Pressure Volume Loops and Ultrasound-derived "Cardiac Power" by Comparison With Invasive Left Ventricular Pressure Volume Loops
Status: Enrolling
Updated: 12/12/2012
University of Virginia
mi
from
Charlottesville, VA
Click here to add this to my saved trials
Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients
A 104 Week, Randomized, Double Blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy of Aliskiren on the Progression of Atherosclerosis in Patients With Coronary Artery Disease When Added to Optimal Background Therapy
Status: Enrolling
Updated:  12/13/2012
Novartis Investigative Site
mi
from
Birmingham, AL
Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients
A 104 Week, Randomized, Double Blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy of Aliskiren on the Progression of Atherosclerosis in Patients With Coronary Artery Disease When Added to Optimal Background Therapy
Status: Enrolling
Updated: 12/13/2012
Novartis Investigative Site
mi
from
Birmingham, AL
Click here to add this to my saved trials
Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients
A 104 Week, Randomized, Double Blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy of Aliskiren on the Progression of Atherosclerosis in Patients With Coronary Artery Disease When Added to Optimal Background Therapy
Status: Enrolling
Updated:  12/13/2012
Novartis Investigative Site
mi
from
Phoenix, AZ
Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients
A 104 Week, Randomized, Double Blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy of Aliskiren on the Progression of Atherosclerosis in Patients With Coronary Artery Disease When Added to Optimal Background Therapy
Status: Enrolling
Updated: 12/13/2012
Novartis Investigative Site
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients
A 104 Week, Randomized, Double Blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy of Aliskiren on the Progression of Atherosclerosis in Patients With Coronary Artery Disease When Added to Optimal Background Therapy
Status: Enrolling
Updated:  12/13/2012
Novartis Investigative site
mi
from
Los Angeles, CA
Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients
A 104 Week, Randomized, Double Blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy of Aliskiren on the Progression of Atherosclerosis in Patients With Coronary Artery Disease When Added to Optimal Background Therapy
Status: Enrolling
Updated: 12/13/2012
Novartis Investigative site
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients
A 104 Week, Randomized, Double Blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy of Aliskiren on the Progression of Atherosclerosis in Patients With Coronary Artery Disease When Added to Optimal Background Therapy
Status: Enrolling
Updated:  12/13/2012
Novartis Investigative site
mi
from
Aurora, CO
Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients
A 104 Week, Randomized, Double Blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy of Aliskiren on the Progression of Atherosclerosis in Patients With Coronary Artery Disease When Added to Optimal Background Therapy
Status: Enrolling
Updated: 12/13/2012
Novartis Investigative site
mi
from
Aurora, CO
Click here to add this to my saved trials
Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients
A 104 Week, Randomized, Double Blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy of Aliskiren on the Progression of Atherosclerosis in Patients With Coronary Artery Disease When Added to Optimal Background Therapy
Status: Enrolling
Updated:  12/13/2012
Novartis Investigative Site
mi
from
Hartford, CT
Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients
A 104 Week, Randomized, Double Blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy of Aliskiren on the Progression of Atherosclerosis in Patients With Coronary Artery Disease When Added to Optimal Background Therapy
Status: Enrolling
Updated: 12/13/2012
Novartis Investigative Site
mi
from
Hartford, CT
Click here to add this to my saved trials
Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients
A 104 Week, Randomized, Double Blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy of Aliskiren on the Progression of Atherosclerosis in Patients With Coronary Artery Disease When Added to Optimal Background Therapy
Status: Enrolling
Updated:  12/13/2012
Novartis Investigative Site
mi
from
Washington,
Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients
A 104 Week, Randomized, Double Blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy of Aliskiren on the Progression of Atherosclerosis in Patients With Coronary Artery Disease When Added to Optimal Background Therapy
Status: Enrolling
Updated: 12/13/2012
Novartis Investigative Site
mi
from
Washington,
Click here to add this to my saved trials
Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients
A 104 Week, Randomized, Double Blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy of Aliskiren on the Progression of Atherosclerosis in Patients With Coronary Artery Disease When Added to Optimal Background Therapy
Status: Enrolling
Updated:  12/13/2012
Novartis Investigative Site
mi
from
Miami, FL
Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients
A 104 Week, Randomized, Double Blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy of Aliskiren on the Progression of Atherosclerosis in Patients With Coronary Artery Disease When Added to Optimal Background Therapy
Status: Enrolling
Updated: 12/13/2012
Novartis Investigative Site
mi
from
Miami, FL
Click here to add this to my saved trials
Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients
A 104 Week, Randomized, Double Blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy of Aliskiren on the Progression of Atherosclerosis in Patients With Coronary Artery Disease When Added to Optimal Background Therapy
Status: Enrolling
Updated:  12/13/2012
Novartis Investigative site
mi
from
Gainesville, GA
Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients
A 104 Week, Randomized, Double Blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy of Aliskiren on the Progression of Atherosclerosis in Patients With Coronary Artery Disease When Added to Optimal Background Therapy
Status: Enrolling
Updated: 12/13/2012
Novartis Investigative site
mi
from
Gainesville, GA
Click here to add this to my saved trials
Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients
A 104 Week, Randomized, Double Blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy of Aliskiren on the Progression of Atherosclerosis in Patients With Coronary Artery Disease When Added to Optimal Background Therapy
Status: Enrolling
Updated:  12/13/2012
Novartis Investigative Site
mi
from
Beach Grove, IN
Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients
A 104 Week, Randomized, Double Blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy of Aliskiren on the Progression of Atherosclerosis in Patients With Coronary Artery Disease When Added to Optimal Background Therapy
Status: Enrolling
Updated: 12/13/2012
Novartis Investigative Site
mi
from
Beach Grove, IN
Click here to add this to my saved trials
Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients
A 104 Week, Randomized, Double Blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy of Aliskiren on the Progression of Atherosclerosis in Patients With Coronary Artery Disease When Added to Optimal Background Therapy
Status: Enrolling
Updated:  12/13/2012
Novartis Investigative Site
mi
from
Louisville, KY
Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients
A 104 Week, Randomized, Double Blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy of Aliskiren on the Progression of Atherosclerosis in Patients With Coronary Artery Disease When Added to Optimal Background Therapy
Status: Enrolling
Updated: 12/13/2012
Novartis Investigative Site
mi
from
Louisville, KY
Click here to add this to my saved trials
Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients
A 104 Week, Randomized, Double Blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy of Aliskiren on the Progression of Atherosclerosis in Patients With Coronary Artery Disease When Added to Optimal Background Therapy
Status: Enrolling
Updated:  12/13/2012
Novartis Investigative Site
mi
from
New Orleans, LA
Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients
A 104 Week, Randomized, Double Blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy of Aliskiren on the Progression of Atherosclerosis in Patients With Coronary Artery Disease When Added to Optimal Background Therapy
Status: Enrolling
Updated: 12/13/2012
Novartis Investigative Site
mi
from
New Orleans, LA
Click here to add this to my saved trials
Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients
A 104 Week, Randomized, Double Blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy of Aliskiren on the Progression of Atherosclerosis in Patients With Coronary Artery Disease When Added to Optimal Background Therapy
Status: Enrolling
Updated:  12/13/2012
Novartis Investigative Site
mi
from
Baltimore, MD
Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients
A 104 Week, Randomized, Double Blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy of Aliskiren on the Progression of Atherosclerosis in Patients With Coronary Artery Disease When Added to Optimal Background Therapy
Status: Enrolling
Updated: 12/13/2012
Novartis Investigative Site
mi
from
Baltimore, MD
Click here to add this to my saved trials
Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients
A 104 Week, Randomized, Double Blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy of Aliskiren on the Progression of Atherosclerosis in Patients With Coronary Artery Disease When Added to Optimal Background Therapy
Status: Enrolling
Updated:  12/13/2012
Novartis Investigative site
mi
from
Boston, MA
Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients
A 104 Week, Randomized, Double Blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy of Aliskiren on the Progression of Atherosclerosis in Patients With Coronary Artery Disease When Added to Optimal Background Therapy
Status: Enrolling
Updated: 12/13/2012
Novartis Investigative site
mi
from
Boston, MA
Click here to add this to my saved trials
Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients
A 104 Week, Randomized, Double Blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy of Aliskiren on the Progression of Atherosclerosis in Patients With Coronary Artery Disease When Added to Optimal Background Therapy
Status: Enrolling
Updated:  12/13/2012
Novartis Investigative Site
mi
from
Ann Arbor, MI
Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients
A 104 Week, Randomized, Double Blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy of Aliskiren on the Progression of Atherosclerosis in Patients With Coronary Artery Disease When Added to Optimal Background Therapy
Status: Enrolling
Updated: 12/13/2012
Novartis Investigative Site
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients
A 104 Week, Randomized, Double Blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy of Aliskiren on the Progression of Atherosclerosis in Patients With Coronary Artery Disease When Added to Optimal Background Therapy
Status: Enrolling
Updated:  12/13/2012
Novartis Investigative Site
mi
from
Rochester, MN
Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients
A 104 Week, Randomized, Double Blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy of Aliskiren on the Progression of Atherosclerosis in Patients With Coronary Artery Disease When Added to Optimal Background Therapy
Status: Enrolling
Updated: 12/13/2012
Novartis Investigative Site
mi
from
Rochester, MN
Click here to add this to my saved trials
Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients
A 104 Week, Randomized, Double Blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy of Aliskiren on the Progression of Atherosclerosis in Patients With Coronary Artery Disease When Added to Optimal Background Therapy
Status: Enrolling
Updated:  12/13/2012
Novartis Investigative Site
mi
from
St Louis, MO
Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients
A 104 Week, Randomized, Double Blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy of Aliskiren on the Progression of Atherosclerosis in Patients With Coronary Artery Disease When Added to Optimal Background Therapy
Status: Enrolling
Updated: 12/13/2012
Novartis Investigative Site
mi
from
St Louis, MO
Click here to add this to my saved trials